To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.

Legislative bill overview

HR 7902 seeks to withdraw FDA approval for mifepristone (a medication used in chemical abortions) and establish a federal tort allowing women to sue for damages they claim resulted from use of the drug. The bill creates new federal legal liability for entities involved in dispensing or administering mifepristone for pregnancy termination.

Why is this important

This legislation would effectively prohibit access to medication abortion nationwide by invalidating existing FDA approval, overriding the agency's scientific determinations made through formal regulatory processes. It would create an entirely new category of federal tort law allowing civil litigation, potentially affecting doctors, pharmacies, and abortion providers while significantly impacting reproductive healthcare access for millions of Americans.

Potential points of contention

• FDA authority and reversal of precedent: The bill overrides the FDA's 2023 decision to expand mifepristone access, raising questions about Congressional power to override independent agency determinations and scientific findings
• Definition and causation of "harm": The bill establishes a tort without clearly defining what constitutes compensable harm or how causation would be established in litigation, potentially creating liability for unpredictable medical outcomes
• Conflict with existing law: This conflicts with state laws that protect or permit medication abortion, creating enforcement and jurisdictional complications across different legal regimes